|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Management of the primary tumor in patients with metastatic pancreatic neuroendocrine tumor: a contemporary single-institution review显示文摘 | Matias Bruzoni Purvi Parikh Rolando Celis Chandrakanth Are Quan P. Ly Jane L. Meza Aaron R. Sasson | 2009 | The American Journal of Surgery2009，，3： | 2 |
| 2 | Bile acid indices as biomarkers for liver diseases I:Diagnostic markers显示文摘BACKGROUND Hepatobiliary diseases result in the accumulation of toxic bile acids(BA)in the liver,blood,and other tissues which may contribute to an unfavorable prognosis.AIM To discover and validate diagnostic biomarkers of cholestatic liver diseases based on the urinary BA profile.METHODS We analyzed urine samples by liquid chromatography-tandem mass spectrometry and compared the urinary BA profile between 300 patients with hepatobiliary diseases vs 103 healthy controls by statistical analysis.The BA profile was characterized using BA indices,which quantifies the composition,metabolism,hydrophilicity,and toxicity of the BA profile.BA indices have much lower interand intra-individual variability compared to absolute concentrations of BA.In addition,BA indices demonstrate high area under the receiver operating characteristic curves,and changes of BA indices are associated with the risk of having a liver disease,which demonstrates their use as diagnostic biomarkers for cholestatic liver diseases.RESULTS Total and individual BA concentrations were higher in all patients.The percentage of secondary BA(lithocholic acid and deoxycholic acid)was significantly lower,while the percentage of primary BA(chenodeoxycholic acid,cholic acid,and hyocholic acid)was markedly higher in patients compared to controls.In addition,the percentage of taurine-amidation was higher in patients than controls.The increase in the non-12α-OH BA was more profound than 12α-OH BA(cholic acid and deoxycholic acid)causing a decrease in the 12α-OH/non-12α-OH ratio in patients.This trend was stronger in patients with more advanced liver diseases as reflected by the model for end-stage liver disease score and the presence of hepatic decompensation.The percentage of sulfation was also higher in patients with more severe forms of liver diseases.CONCLUSION BA indices have much lower inter-and intra-individual variability compared to absolute BA concentrations and changes of BA indices are associated with the risk of developing liver diseases. | Jawaher Abdullah Alamoudi Wenkuan Li Nagsen Gautam Marco Olivera Jane Meza Sandeep Mukherjee Yazen Alnouti | 2021 | World Journal of Hepatology2021，13，4： | 1 |
| 3 | Bile acid indices as biomarkers for liver diseases Ⅱ: The bile acid score survival prognostic model显示文摘BACKGROUND Cholestatic liver diseases are characterized by an accumulation of toxic bile acids(BA)in the liver,blood and other tissues which lead to progressive liver injury and poor prognosis in patients.AIM To discover and validate prognostic biomarkers of cholestatic liver diseases based on the urinary BA profile.METHODS We analyzed urine samples by liquid chromatography-tandem mass spectrometry and investigated the use of the urinary BA profile to develop survival models that can predict the prognosis of hepatobiliary diseases.The urinary BA profile,a set of non-BA parameters,and the adverse events of liver transplant and/or death were monitored in 257 patients with cholestatic liver diseases for up to 7 years.The BA profile was characterized by calculating BA indices,which quantify the composition,metabolism,hydrophilicity,formation of secondary BA,and toxicity of the BA profile.We have developed and validated the bile-acid score(BAS)model(a survival model based on BA indices)to predict the prognosis of cholestatic liver diseases.RESULTS We have developed and validated a survival model based on BA(the BAS model)indices to predict the prognosis of cholestatic liver diseases.Our results demonstrate that the BAS model is more accurate and results in higher truepositive and true-negative prediction of death compared to both non-BAS and model for end-stage liver disease(MELD)models.Both 5-and 3-year survival probabilities markedly decreased as a function of BAS.Moreover,patients with high BAS had a 4-fold higher rate of death and lived for an average of 11 mo shorter than subjects with low BAS.The increased risk of death with high vs low BAS was also 2-4-fold higher and the shortening of lifespan was 6-7-mo lower compared to MELD or non-BAS.Similarly,we have shown the use of BAS to predict the survival of patients with and without liver transplant(LT).Therefore,BAS could be used to define the most seriously ill patients,who need earlier intervention such as LT.This will help provide guidance for timely care for liver patients.CONCLUSION The BAS model is more accurate than MELD and non-BAS models in predicting the prognosis of cholestatic liver diseases. | Jawaher Abdullah Alamoudi Wenkuan Li Nagsen Gautam Marco Olivera Jane Meza Sandeep Mukherjee Yazen Alnouti | 2021 | World Journal of Hepatology2021，13，5： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员